Press Releases
Search
-
04 Sep 2012
bioMérieux - First-Half Results at June 30, 2012
Solid financial performance: €128 million in operating income before non-recurring items, up 6.5% Strong increase in cash flow Faster expansion in emerging markets: India: acquisition of molecular bio...
-
19 Jul 2012
bioMérieux - First-Half 2012 Business Review
Sales Up 8.7% at constant exchange rates Of which 2.9% through organic growth bioMérieux China becomes the Group's 3rd largest company, with sales up 48%* Solid 22%* growth in sales of the Full Microb...
-
03 May 2012
bioMérieux Completes its VIDAS® Hepatitis Panel with a New Test for the Diagnosis of Hepatitis C
Marcy l’Etoile, France, May 3, 2012 — bioMérieux, a world leader in the field of in vitro diagnostics, announces the launch of VIDAS® Anti-HCV for the detection of the hepatitis C virus (HCV). With th...
-
24 Apr 2012
bioMérieux - First-Quarter 2012 Business Review
Sales up 9.3% at constant exchange rates Of which 3.1% organic growth, in line with objectives Strong momentum* in China (up 47%) and India (up 31%) Solid performance* in industrial applications (up 1...
-
12 Apr 2012
bioMérieux’s Myla® Named as Finalist in the 2012 Medical Design Excellence Awards
Myla middleware recognized for groundbreaking innovation in In Vitro Diagnostics...
-
27 Mar 2012
Detection of Schmallenberg virus made possible by bioMérieux: the ADIAGENE PCR kit has been validated by ANSES
Marcy l’Etoile, France – ADIAGENE, a member of the bioMérieux group and specialized in diagnostics for animal health, has obtained ANSES validation for a kit for the detection of Schmallenberg virus, ...
-
13 Mar 2012
bioMérieux - 2011 Financial Results
Solid financial performance: Sales at constant exchange rates: up 6.5% Including organic growth: up 4.1% Operating margin before non-recurring items: 18% Confirmed medium and long-term growth potentia...
-
14 Feb 2012
biomerieux-issues-reminder
Marcy l'Etoile - bioMérieux issues a reminder that on January 24, 2012, it set and communicated its objectives for 2012 sales growth. The Company is targeting organic growth between 3-5% or 6-8% at co...
-
24 Jan 2012
bioMérieux - 2011 Business Review
Sales: Up 6.5% at constant exchange rates Including 4.1% organic growth Double-digit growth* in 11 countries Including: India** (up 28%), China (up 20%), Brazil (up 18%) and Turkey (up 18%) Sustained ...
-
14 Dec 2011
Information following the December 7th press release
Marcy l’Etoile (France) - December 14, 2011. At the request of the French “Autorité des Marchés Financiers”, bioMérieux, a world leader in the field of in vitro diagnostics, completes the information ...
-
07 Dec 2011
bioMérieux - Information on 2011 sales objective
Marcy l’Etoile (France) - December 7, 2011. bioMérieux, a world leader in the field of in vitro diagnostics,announces that, based on preliminary data, sales growth at constant exchange rates, for the ...
-
18 Nov 2011
bioMérieux Initiative to Support European Antibiotic Awareness Day
Marcy l’Etoile (France) - November 18, 2011. As the world leader in microbiology and a pioneer in diagnostics for antimicrobial resistance detection and susceptibility testing (AST), bioMérieux active...
-
04 Nov 2011
bioMérieux and Biocartis Sign Strategic Partnership in Molecular Diagnostics
Marcy l'Etoile, France and Lausanne (Switzerland) - November 4, 2010. Co-development of assays and co-distribution of a fully integrated molecular platform due for launch in 2012. bioMérieux gains exc...
-
20 Oct 2011
bioMérieux Business Review for the nine months ended September 30, 2011
Marcy l'Etoile, France - October 20, 2011. Sales: Up 5.2% at constant exchange rates Including 4% organic growth Robust 8% organic growth in clinical microbiology Double-digit organic growth continues...
-
28 Sep 2011
Mise en œuvre du retrait obligatoire visant les actions AES Chemunex
Marcy L'Etoile, France - September 28, 2011. Communiqué de mise à disposition de la note d’information de bioMérieux et de la note en réponse d’AES Chemunex visées par l’AMF, ainsi que des information...